Nowarta110 for Cervical Dysplasia

About Nowarta Biopharma

Nowarta Biopharma is a private, pre-revenue biotech founded in 2020, advancing a novel botanical drug candidate, Nowarta110, through clinical development. The company's lead program targets HPV-induced plantar warts, having demonstrated a 64.3% complete lesion clearance rate with zero serious adverse events in a Phase I/II study, with a Phase 3 trial planned for 2026. Nowarta is pursuing an ambitious pipeline expansion into cervical dysplasia (CIN 2,3), COVID-19, and skin cancers, leveraging regulatory designations like Fast Track, though its early-stage and broad focus present significant development and execution risks.

Therapeutic Areas